Rectal Cancer
Rectal Carcinoma
Male, 64 years
Patient Internal ID 372282674
ICD-10 code
C20 Malignant Neoplasm of Rectum
Diagnosis (Incl. Metastases/Stage) and Year
2013
Rectal Carcinoma pT4N0M0 G2 Stage IIB (2013). Disease progression in February 2017 – Multiple Metastases in the Lungs. In February 2020, Disease progression in the Lungs.
Previous Treatment
Surgery (Rectal resection), Chemotherapy (FOLFOX4), Surgery (Resection of Lung Metastasis), Chemotherapy (FOLFOX) + Biologic Therapy (Bevacizumab), Chemotherapy (Capecitabine) + Biologic Therapy (Bevacizumab), Chemotherapy (FOLFIRI) + Biologic Therapy (Bevacizumab), Chemotherapy (Trifluridine/ Tipiracil), Target Therapy (Regorafenib).
Prognosis and Survival Expectation
The prognosis remains poor for Advanced Rectal Cancer, with a median survival of ~28 months from diagnosis.
Treatment Provided
Autologous DCV (10 doses) and CIK (4 doses) over a period of 14 months.
Patient Survival/Condition and Year
Date of Review: 30/12/2023
The patient has survived for 10 years since the diagnosis, and 6 years and 8 months since the disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapies, Biological Therapy and Target Therapy, has extended patient survival by an estimate of around 52 months.
